Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients-Reference-Cited by-同舟云学术

Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients

Published:2013-02-18 Issue:1 Volume:14 Page:
ISSN:1471-2369
Container-title:BMC Nephrology
language:en
Short-container-title:BMC Nephrol

Author:

Hutchison Alastair J,Gill Maggie,Copley J Brian,Poole Lynne,Wilson Rosamund J

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Link

http://link.springer.com/article/10.1186/1471-2369-14-40/fulltext.html

Reference25 articles.

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998, 31: 607-617. 10.1053/ajkd.1998.v31.pm9531176.

2. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000, 35: 1226-1237. 10.1016/S0272-6386(00)70064-3.

3. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005, 16: 520-528. 10.1681/ASN.2004070602.

4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004, 15: 2208-2218. 10.1097/01.ASN.0000133041.27682.A2.

5. Eknoyan G, Levin A, Levin N: National kidney foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003, 42 (Suppl 3): S1-S201.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term safety of lanthanum carbonate in the real word: a 19-year disproportionality analysis from the FDA Adverse Event Reporting System;Expert Opinion on Drug Safety;2024-04-15

2. Phosphorus balance calculator: an individualized tool for treatment of hyperphosphatemia in hemodialysis patients;Nephrology Dialysis Transplantation;2023-11-30

3. Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate;Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis;2023-09-10

4. An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis;BMC Nephrology;2022-03-02

5. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis;Renal Failure;2021-01-01